Project abstract for group baughnl

Understanding Bortezomib Resistance

Multiple myeloma (MM), the second most common hematopoietic malignancy, remains an incurable plasma cell (PC) neoplasm. While the proteasome inhibitor bortezomib (Bz) has increased patient survival, resistance represents a major treatment obstacle as most patients ultimately relapse becoming refractory to additional Bz therapy. Current tests fail to detect emerging resistance; by the time patients acquire resistance, their prognosis is often poor. This group has identified a set of genes that may indicate a mechanism for Bz-resistance through the loss of PC maturation which may be induced and/or selected by Bz. They are using software available at MSI for analyzing mutations in genes that might confer Bz resistance.